Omega Therapeutics (OMGA) Research Analysts’ Weekly Ratings Changes – Defense World

Posted: June 13, 2022 at 2:13 am

A number of firms have modified their ratings and price targets on shares of Omega Therapeutics (NASDAQ: OMGA) recently:

Omega Therapeutics stock opened at $3.70 on Friday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 15.23 and a current ratio of 15.23. The firm has a market capitalization of $177.05 million and a price-to-earnings ratio of -0.77. Omega Therapeutics, Inc. has a fifty-two week low of $1.98 and a fifty-two week high of $31.41. The stocks fifty day moving average is $3.85 and its two-hundred day moving average is $8.97.

Omega Therapeutics (NASDAQ:OMGA Get Rating) last posted its quarterly earnings data on Thursday, March 10th. The company reported ($0.44) EPS for the quarter, beating analysts consensus estimates of ($0.57) by $0.13. The company had revenue of $0.14 million for the quarter. As a group, sell-side analysts forecast that Omega Therapeutics, Inc. will post -2.17 EPS for the current fiscal year.

Omega Therapeutics, Inc operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer.

Read More

Receive News & Ratings for Omega Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omega Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Visit link:
Omega Therapeutics (OMGA) Research Analysts' Weekly Ratings Changes - Defense World

Related Post